Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.00p -2.95% 263.50p 264.00p 265.00p 271.50p 264.00p 271.50p 244,075 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 28.7 5.1 0.8 337.8 1,742.32

Syncona Share Discussion Threads

Showing 18476 to 18500 of 18500 messages
Chat Pages: 740  739  738  737  736  735  734  733  732  731  730  729  Older
DateSubjectAuthorDiscuss
13/12/2018
09:34
Just a bit more about potential from Blue Earth website “Fluciclovine F 18 is an artificial amino acid that has been labelled with F 18 to allow positron emission tomography (PET) imaging. Fluciclovine F 18 appears to be avidly taken up by a number of cancer cell types, including prostate cancer and glioma (a type of brain tumour). Blue Earth Diagnostics is investigating fluciclovine F 18 as a molecular diagnostic imaging agent for various cancers. It has been evaluated most extensively for disease localisation and detection in prostate cancer patients with suspected biochemical recurrence following earlier treatment. Prostate Cancer Blue Earth Diagnostics’ first product, Axumin™ (fluciclovine F 18), was approved by the U.S. Food & Drug Administration (FDA) in May 2016 for use in PET imaging of biochemically recurrent prostate cancer. In May 2017, the European Medicines Agency (EMA) granted marketing authorisation for Axumin use in PET imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. Blue Earth Diagnostics filed for marketing approval for Axumin with both the FDA and the EMA based on studies conducted on over 800 subjects in the USA, Italy and Norway. In May 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Glioma Blue Earth Diagnostics has obtained Orphan Drug Designation (ODD) from the FDA and the EMA for the use of fluciclovine F 18 in the diagnosis of glioma, a form of brain cancer. Gliomas make up about 30% of all brain and central nervous system tumours and 80% of all malignant brain tumours. The symptoms, prognosis, and treatment of a malignant glioma depend on the person’s age, the exact type of tumour, and the location of the tumour – which often penetrates deep into the brain. Blue Earth Diagnostics plans to investigate the role of fluciclovine F 18 PET imaging in evaluating the spread of both high and low grade glioma within the brains of affected patients. Other diseases The company anticipates the development of follow-on indications for fluciclovine 18 in the diagnosis of other tumour types, as well as other applications in prostate cancer.
brexitplus
12/12/2018
19:39
Axumin( Blue Earth) now available in France
ltinvestor
12/12/2018
11:25
Lux Yes, more great news today. I’ve contacted Syncona to ask if they will be issuing their usual RNSs about the two releases. It appears the Blue Earth news, according to Syncona, only justifies going out via their email to investors. So sign up today!!!
brexitplus
12/12/2018
11:15
Blue Earth on a roll by the sounds of it hxxp://www.blueearthdiagnostics.com/first-production-and-administration-of-axumin-fluciclovine-18f-in-france/ First patients commercially dosed in France (for prostate). Update: "Axumin is commercially available in France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria with further European countries set to follow soon."
luxaeterna1
12/12/2018
07:01
This is new news, following publication of test results on 19th November. Well spotted. I’m surprised Syncona didn’t release an RNS.
brexitplus
11/12/2018
14:05
hxxps://www.synconaltd.com/investors/news/blue-earth-diagnostics-announces-us-food-and-drug-administration-fda-filing-acceptance-of-supplemental-new-drug-application-snda-for-18f-fluciclovine-pet-imaging-in-glioma/?accept_disclaimer=true it appears that Blue Earth have sent Axumin phase 3 trial data to the FDA for a second condition, ie cancerous brain gliomas. I am not 100% clear if this is major news or just ongoing pr.
luxaeterna1
06/12/2018
16:35
Autolus doing well despite the US falls.
brexitplus
21/11/2018
18:50
https://www.proactiveinvestors.co.uk/companies/news/209677/nightstar-therapeutics-deserves-a-spot-on-your-watchlist-if-you-are-an-aggressive-biotech-investor-209677.html
ltinvestor
21/11/2018
18:18
Results presentation: httPs://www.synconaltd.com/media/1316/syncona-interim-presentation-201118-final.pdf and webcast available here: htTps://www.synconaltd.com/investors/results-centre/?accept_disclaimer=true
rambutan2
21/11/2018
08:28
Syncona also made charitable donations of £4.7m during the last year.This, IMO, is an exceptional company...
ltinvestor
21/11/2018
08:15
I wouldn’t be surprised if there is a lot of outside interest in Blue Earth. User numbers increasing quickly. Large newsflow in the past few months. Profitable.
brexitplus
21/11/2018
08:01
Very good numbers! Happy days. DL
davidlloyd
21/11/2018
07:32
As I said over a year ago when the share price was around £1.70.Buy,sit back and watch the growth....Blue Earth diagnostics very undervalued in the accounts...
ltinvestor
21/11/2018
07:28
Excellent interims.
brexitplus
19/11/2018
14:59
Autolus share price all over the place recently but looks like an upward trend. Nightstar a bit variable.
brexitplus
13/11/2018
07:25
Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), has announced the initiation of its Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and has reported Third Quarter 2018 Financial Results. The announcement can be accessed on Nightstar's investor website at hxxp://ir.nightstartx.com
brexitplus
10/11/2018
16:21
Nightstar up $2.5 in 3 days and presenting this coming week in London and two weeks later in New York.Presently $12.5 and wouldn’t be surprised to see $18 by end Dec
ltinvestor
10/11/2018
06:27
Autolus finished at $48 last night with a high of $53.
brexitplus
09/11/2018
09:24
Autolus spike ~30% last night in the US - News? New investor?
luxaeterna1
09/11/2018
08:01
Bought Nightstar at $10....raised $80m a few weeks ago at $18!!
ltinvestor
07/11/2018
16:59
Yes...there are 15 types of cancers targeted on page 10.
luxaeterna1
07/11/2018
15:10
Thanks Lux Impressive presentation. With so much going on its hard to keep up!!!
brexitplus
07/11/2018
10:57
Thanks Brexitplus, I also noticed a September 2018 Autolus presentation on the Autolus page hTtps://www.autolus.com/investor-relations/news-events/presentations
luxaeterna1
02/11/2018
22:09
There is a Syncona presentation at the Numis Mid-Cap Conference dated 31/10/2018 on the Syncona website.
brexitplus
02/11/2018
11:08
hxxps://ash.confex.com/ash/2018/webprogram/Paper118050.html Apparently the text overview of the Freeline paper on Haemophilia. Can't think how these two trials could have gone any better "Results: As of 26 June 2018, two patients had been treated with FLT180a at the low dose of 4.5 x 1011 vg/kg and observed for 20 and 14 weeks, respectively. Within 4 weeks of receiving a single infusion of FLT180a, both patients achieved FIX levels of >30%, which is well within the mild haemophilia range where the risk of spontaneous bleeding is absent and bleeding occurs only after major surgery or injury. Patients 1 and 2 had peak FIX expression around Week 12 with levels of 48% and 66%, respectively. After the discontinuation of prophylactic steroids FIX levels stabilised at 46% and 48%, respectively. No serious adverse events have been reported and there has not been any significant increase in liver enzymes. Prophylaxis with exogenous coagulation factor was stopped within the first week post FLT180a administration due to sufficient rise in patients endogenous FIX. Neither patient has required exogenous coagulation factor after this first week. No spontaneous bleeds have occurred. A traumatic bleed was reported by Patient 1 (right middle finger cut) at Week 10 but did not require treatment with FIX concentrates. The patient’s FIX activity at the time was 38%."
luxaeterna1
Chat Pages: 740  739  738  737  736  735  734  733  732  731  730  729  Older
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181213 17:53:33